However, only a subset of cancer patients benefit from anti-PD1/PD-L1 therapy with an objective response rate less than 45% in melanoma, less than 20% in NSCLC, and 20–25% in RCC and CRC [155,156,157,158,159]. This evidence concerns the gene CD274 and melanoma.